160 related articles for article (PubMed ID: 34117035)
1. Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors.
He X; Ji J; Dai X; Qdaisat AZ; Esteva FJ; Hortobagyi GN; Yeung SJ
Clin Cancer Res; 2021 Oct; 27(19):5343-5352. PubMed ID: 34117035
[TBL] [Abstract][Full Text] [Related]
2. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
[TBL] [Abstract][Full Text] [Related]
3. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
4. Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59 at diagnosis: A nationwide study.
Chung IY; Lee JW; Moon HG; Shin KH; Han W; Son BH; Ahn SH; Noh DY
Breast; 2020 Oct; 53():125-129. PubMed ID: 32771950
[TBL] [Abstract][Full Text] [Related]
5. Long-term risk of congestive heart failure in younger breast cancer survivors: A nationwide study by the SMARTSHIP group.
Lee J; Hur H; Lee JW; Youn HJ; Han K; Kim NW; Jung SY; Kim Z; Kim KS; Lee MH; Han SH; Jung SH; Chung IY
Cancer; 2020 Jan; 126(1):181-188. PubMed ID: 31454422
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
8. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
[TBL] [Abstract][Full Text] [Related]
9. Hypertension Susceptibility Loci are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors.
Hildebrandt MAT; Reyes M; Wu X; Pu X; Thompson KA; Ma J; Landstrom AP; Morrison AC; Ater JL
Sci Rep; 2017 Aug; 7(1):9698. PubMed ID: 28851949
[TBL] [Abstract][Full Text] [Related]
10. Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.
Gong IY; Verma S; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Brezden-Masley CB; Gavura S; Peacock S; Chan KK
Breast Cancer Res Treat; 2016 Jun; 157(3):535-44. PubMed ID: 27271767
[TBL] [Abstract][Full Text] [Related]
11. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
12. The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population.
Law W; Johnson C; Rushton M; Dent S
Curr Oncol; 2017 Oct; 24(5):e348-e353. PubMed ID: 29089804
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline-induced cardiotoxicity in patients with paediatric bone sarcoma and soft tissue sarcoma.
Bini I; Asaftei SD; Riggi C; Tirtei E; Manicone R; Biasin E; Basso ME; Agnoletti G; Fagioli F
Cardiol Young; 2017 Nov; 27(9):1815-1822. PubMed ID: 28780919
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity screening of long-term, breast cancer survivors-The CAROLE (Cardiac-Related Oncologic Late Effects) Study.
Puckett LL; Saba SG; Henry S; Rosen S; Rooney E; Filosa SL; Gilbo P; Pappas K; Laxer A; Eacobacci K; Kapyur AN; Robeny J; Musial S; Chaudhry A; Chaudhry R; Lesser ML; Riegel A; Ramoutarpersaud S; Rahmani N; Shah A; Papas V; Dawodu T; Charlton J; Knisely JPS; Lee L
Cancer Med; 2021 Aug; 10(15):5051-5061. PubMed ID: 34245128
[TBL] [Abstract][Full Text] [Related]
16. Risk of cardiotoxicity induced by adjuvant anthracycline-based chemotherapy and radiotherapy in young and old Asian women with breast cancer.
Lee CH; Zhang JF; Yuan KS; Wu ATH; Wu SY
Strahlenther Onkol; 2019 Jul; 195(7):629-639. PubMed ID: 30690687
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
Shibata T; Nohara S; Morikawa N; Shibao K; Ito S; Shibata R; Toh U; Nagafuji K; Fukami K; Fukumoto Y
Eur J Prev Cardiol; 2023 Dec; 30(18):1941-1949. PubMed ID: 37352112
[TBL] [Abstract][Full Text] [Related]
18. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
[TBL] [Abstract][Full Text] [Related]
19. The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
Pearson EJ; Nair A; Daoud Y; Blum JL
Breast Cancer Res Treat; 2017 Feb; 162(1):59-67. PubMed ID: 28066861
[TBL] [Abstract][Full Text] [Related]
20. Anthracycline cardiotoxicity after breast cancer treatment.
Hershman DL; Shao T
Oncology (Williston Park); 2009 Mar; 23(3):227-34. PubMed ID: 19418823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]